In a research note published today, Maxim Group analyst Jason Kolbert assigned a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as …
In a report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on IsoRay Inc (NYSE:ISR) with a $5 price target, following …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and slightly raised his …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $4 price …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a $7 price target, as the …
In a research report issued yesterday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a price target …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) with a $127 price …
In a research note issued today, Maxim Group analyst Jason Kolbert assigned a Buy rating on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) with a $24 price target, …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NYSE:INO) with a $18 price target, as the …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Synthetic Biologics (NYSE:SYN) with a $6 price target, after the company held an R&D day on …
